Service alert

Molecular Testing and the Measles Milestone

11/18/2026
Podcast

November 18, 2026

New Surveys and Anatomic Pathology Education Programs – CAP

American Cancer Society Updates Prostate Cancer Screening Guideline: Major Changes Include Regular PSA Testing for Average and High-Risk Men

Stories From The Frontlines: Mergers And Acquisitions – CAP

One Size Fits Nobody: Shifts in Private Practice in 2026 

Elizabeth McMahon

Coming up, a sad designation for the country's measles elimination status, and why molecular testing can help identify cases more rapidly. Plus, navigating the dreaded reorg. Pathologists who've been through structural change offer their perspective. Welcome to CAP News for Wednesday, November 18th. I'm Elizabeth McMahon of the College of American Pathologists. Here's what's making news in pathology and laboratory medicine. In a grim public health milestone, the U.S. has lost its measles elimination status after more than 25 years. The designation means that measles has been spreading in the U.S. for 12 months or more. Confirmed measles cases have soared this year to more than 5,400, according to the latest data from the Centers for Disease Control and Prevention.

Dr. Ben Bradley

These outbreaks at least have started in communities that are maybe more skeptical of going to medical providers, are more skeptical of receiving treatment. And so if these people do get sick, they're probably not going to go to get tested for measles. They're just going to say, I guess I had measles, and that's that. So, you know, the numbers that we're seeing of positive cases are, I think, a very large underestimate of the total burden of disease that's been here.

Elizabeth McMahon

That's Dr. Ben Bradley, a clinical microbiologist at the University of Utah and medical director at ARUP Laboratories. Molecular testing has become an important tool for clinical laboratories to accurately detect the virus and distinguish between vaccine-related reactions and true infections. The CAP's molecular proficiency test for measles, mumps, rubella, and varicella zoster virus closely mirrors clinical laboratory workflows.

Dr. Ben Bradley

By building assays that can separate out that wild type true measles infection from vaccine strain, you can say, all right, I know you just had a reaction to the vaccine. I'm not super worried about you. What we want to avoid is basically ticking off all the boxes of all the possible types of lab tests that could present in a patient with slightly abnormal bleeding factors and or a suspected bleeding history. So having our PT material also have analytes that can test for either of those, I think, is important too, because that's really something that we're trying to understand a little bit more and bring in more into our clinical testing realm as well.

Elizabeth McMahon

The CDC has reported six measles-related deaths in 2026, though State Health Departments have reported ten. In other news, the American Cancer Society now recommends that men age 50 to 69 with average risk do a prostate-specific antigen or PSA screening every two years to detect and reduce their risk of prostate cancer. The society also recommends annual PSA-based screening beginning at age 45 for black men and men with a strong family history of prostate cancer. The new recommendations reflect increasing evidence that screening with a PSA test significantly reduces prostate cancer mortality and diagnosis of advanced stage disease. The previous prostate cancer screening guideline published in 2010 did not include a direct recommendation for regular PSA-based screening. The reorg. For some, the term signifies a fresh, new direction, while for others it incites dread. But what really happens when health systems merge or practices make major changes up and down the organizational chart? A December 8th webinar from 1 to 3 p.m. Central Time will give you perspectives from those who have lived through mergers and acquisitions and learned lessons from the process. Participants will walk away with practical strategies for maintaining diagnostic quality and retaining personnel while preserving their professional autonomy during major systemic change. And finally, if you're in private practice and a reorganization or structural change is in your future, Cap on Demand can also offer some perspective. The streaming service, exclusively for members, has hundreds of sessions spanning various professional topics, including one centered on shifts in private practice in 2026. Panelist Dr. Karim Sirgi, CEO of Sirgi Consulting, says more than half of pathology practices have consolidated in the U.S. in recent years, a trend that has had a paradoxical effect.

Dr. Karim Sirgi

The more the market is consolidating, the more independent groups are thinking and having deep dives, internal deep dive, of why it is that they are independent and whether they want to stay independent.

Elizabeth McMahon

The hour-long discussion includes a look at the realities practices are facing, including Medicare reimbursement rates, that determine whether a practice thrives or becomes the next acquisition target. That's all for today. Be sure to check the show notes for more information on today's stories. Got a story you'd like to hear on the podcast? Write to us at stories at CAP.org. We're back at 5 AM Eastern for another episode of CAP News. I'm Elizabeth McMahon. Have a great day.